|Pfizer's Phase III Study Didn't Meet Primary Endpoint; Boston Scientific Announces Positive Data|
|By Staff and Wire Reports|
|Tuesday, 15 May 2012 18:52|
Pfizer Inc (NYSE:PFE) announced the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL^® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT^® (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
Although PFS was numerically higher in patients treated with temsirolimus, the difference was not statistically significant. Overall survival, a secondary endpoint in the study, showed statistical significance favoring patients randomized to the sorafenib arm. Adverse events in this study were consistent with the known safety profiles for both drugs. Full efficacy and safety data from this study will be presented at an upcoming major medical congress.
Boston Scientific Corporation (NYSE: BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus™ Aortic Valve System in patients with severe aortic valve disease.
The Lotus Aortic Valve System is the first transcatheter aortic valve replacement (TAVR) device of its kind that is designed to minimize aortic regurgitation (leaking) and is both fully repositionable and retrievable prior to release. Data presented today at the annual EuroPCR Scientific Program in Paris demonstrated successful deployment of the valve in all patients with virtually no paravalvular regurgitation after valve placement or at discharge.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will host a live webcast of its Educational Program on Parkinson’s Disease Psychosis to be held with analysts and investors in New York City on Tuesday, May 22, 2012, from 12:00 p.m. to 1:15 p.m. Eastern Time.
Accelr8 Technology Corporation (NYSE MKT: AXK) and Denver Health received notice that the Defense Medical Research and Development Program (DMRDP) recommended $2 million funding of a proposed 35-month project submitted jointly by Denver Health and Accelr8.
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has retired approximately $4.5 million in aggregate convertible debt due on May 12, 2012, October 31, 2012, and January 9, 2013.
American Bio Medica Corporation (ABMC.PK) today announced financial results for the three months ended March 31, 2012.
Antares Pharma, Inc. (NYSE Amex: AIS) today announced the appointment of LeRoux Jooste to the position of Senior Vice President of Pharmaceutical Sales and Marketing.
BioLargo, Inc. (OTCBB: BLGO), creator of patented iodine technologies, today announced the development of novel antimicrobial products for the advanced wound care industry and the formation of a wholly owned subsidiary BioLargo Medical Group, Inc., formed to advance proof of claims and pursue regulatory approvals.
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today reported its results for the quarter ended March 31, 2012.
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), today announced that it has been named one of the "2012 Best Places to Work in the Bay Area" by a joint project of the San Francisco Business Timesand the Silicon Valley/San Jose Business Journal.
Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA® (abatacept).
Cardium Therapeutics (NYSE Amex: CXM) today presented its financial results for the first quarter ended March 31, 2012, and other recent developments.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company will be added to the NASDAQ Biotechnology Index® (NBI), effective prior to market open on Monday, May 21, 2012.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced a reverse split of its common stock at a ratio of 1-for-7.
Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three months ended March 31, 2012.
Fibrocell Science, Inc. (OTCBB:FCSC.OB) announced today the formation of the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives (CIDMOD) Initiative (www.CIDMOD.org) in collaboration with researchers from a number of different universities across the U.S.
Galectin Therapeutics (NASDAQ: GALT) (“the Company”), the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.
Generex Biotechnology Corporation (OTCBB: GNBT), in anticipation ofthe transition into pivotal Phase III trials, is pleased to announce today that the expertise of the Scientific Advisory Board (SAB) of its wholly-owned subsidiary, Antigen Express, Inc., has been expanded by the addition of two globally recognized experts in clinical trial research and immuno-therapeutic treatments of breast cancer.
GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2012 and provided a business update.
Greatbatch, Inc. (NYSE: GB), today announced that Mr. Thomas J. Hook, President and CEO will present at the Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas, NV on Tuesday, May 15, 2012, at 11:20 a.m. Pacific Time.
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the first quarter ended March 31, 2012.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that the company will be added to the NASDAQ Biotechnology Index® (NBI).
InVivo Therapeutics Holdings Corp. (OTCBB:NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today reported the financial results for the three months ended March 31, 2012 and provided a business update.
International Stem Cell Corporation (OTCBB: ISCO) (www.internationalstemcell.com) today announced that several of its leading scientists will present experimental results from three of ISCO’s pre-clinical therapeutic programs.
MeadWestvaco Corporation (NYSE: MWV), a global leader in packaging and packaging solutions, will present at Pharmapack North America’s inaugural conference at the Pennsylvania Convention Center in Philadelphia, May 22 – 23, 2012.
Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Friday, June 1, 2012, in New York City from 9:00 a.m. to approximately 1:00 p.m. Eastern Daylight Time.
NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported today that WellMed Medical Management, a San Antonio, Texas-based diversified healthcare company and healthcare provider, is integrating the NC-stat DPNCheck into their patient evaluation program.
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday, May 15th, 2012 at 8:40 a.m. PT.
Pernix Therapeutics Holdings, Inc. (NYSE Amex: PTX), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2012.
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer, Judy L. Brown, will present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 15, at 10:00 AM (PDT) in Las Vegas, NV.
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its First Quarter 2012 financial results and to provide a business update.
Rite Aid Corporation (NYSE: RAD) announced today that it has closed its previously announced offering of an additional $421.0 million aggregate principal amount of 9.25% Senior Notes due 2020 (the “New Notes”).
Senesco Technologies, Inc. (NYSE Amex: SNT) today reported financial results for the third quarter of fiscal year 2012 which ended on March 31, 2012.
Stellar Pharmaceuticals Inc. (OTCQB:SLXCF) (OTCBB:SLXCF) (PINKSHEETS:SLXCF) ("Stellar" or "the Company"), an emerging specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for the period ended March 31, 2012.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark Approval and launch of its EnligHTN™ renal denervation system during EuroPCR.
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that data from the FAME II trial demonstrated a significant difference in the need for urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with stable coronary artery disease.
Titan Medical Inc. (TSX VENTURE:TMD) (OTCQX:TITXF) announced today results for the three months ended March 31, 2012.
Unilens Vision Inc. (OTCBB: UVIC) (OTCQB: UVIC) (TSX VENTURE: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the third quarter and first nine months of FY2012.
UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that Cardis Furniture (www.cardis.com) has chosen the Company's Viratech UV-400 as the air purifier to be combined with a premium Serta Mattress as the Ultimate Sleep System for promoting a sound sleep.
Approximately one in four U.S. adults lacks adequate prescription drug coverage1, and with both cost savings and access to health care top of mind for many Americans, Walgreens (NYSE, NASDAQ: WAG) has introduced a new and improved Prescription Savings Club program - providing members greater value and covering a more comprehensive range of medications than any similar offering by any major drugstore chain in the marketplace today.